ArticlePharmaceutical research2008
Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Article in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- Local controlled release of stabilized monoclonal antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Inhalation potential of N-Acetylcysteine loaded PLGA nanoparticles for the management of tuberculosis:Current research in pharmacology and drug discovery · 2022Article
- RepositioningPharmaceutics · 2020Article
- Article
- Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.Pharmaceutical research · 2016Article
- Bioavailability of phytochemicals and its enhancement by drug delivery systems.Cancer letters · 2013Review
- Controlled-release systemic delivery - a new concept in cancer chemoprevention.Carcinogenesis · 2012Article
- Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol.Molecular pharmaceutics · 2012Article
- Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.Journal of carcinogenesis · 2011Article
- A rapid method for creating drug implants: translating laboratory-based methods into a scalable manufacturing process.Journal of biomedical materials research. Part B, Applied biomaterials · 2010Article
- Formulation and in vitro-in vivo evaluation of black raspberry extract-loaded PLGA/PLA injectable millicylindrical implants for sustained delivery of chemopreventive anthocyanins.Pharmaceutical research · 2010Article
- Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2008Article
- Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe objective of this study was to develop poly(lactic-co-glycolic acid) (PLGA) injectable implants (i.e., millicylinders) with microencapsulated N-acetylcysteine (NAC) for site-specific controlled NAC release, for potential chemopreventive applications in persons with previously excised head and neck cancers.
methodsPLGA 50:50 (i.v.=0.57 dl/g) implants with 1-10 wt% NAC free acid or 10 wt% NAC salts (NAC-Na+, NAC-Mg2+ and NAC-Ca2+) were prepared by solvent extrusion and/or fluid energy micronization (FEM) methods. X-ray diffraction (XRD), scanning electron microscopy (SEM), and differential scanning calorimetry (DSC) studies were performed to evaluate the physical mixing of NAC with PLGA. PLGA implant degradation was studied by kinetics of polymer molecular weight decline (gel permeation chromatography) and mass loss. Release studies were conducted in N2 purged PBS (pH 7.4) at 37 degrees C in evacuated and sealed ampoules. NAC was quantified by HPLC at 210 nm.
resultsXRD, SEM and DSC studies indicated that NAC had dissolved in the polymer phase at 1-3.5% w/w loading, but became discretely suspended in the polymer at 6-10% w/w. Initial burst and long-term release rate increased with increased drug loading, and release was uncharacteristically rapid at higher loading (6-10% w/w). The cause of the rapid release was linked to extensive plasticization, matrix porosity and general acid catalysis of PLGA degradation caused by the NAC free acid. PLGA millicylinders loaded with 10% w/w NAC-Ca2+ and NAC-Mg2+salts exhibited reduced burst (34 vs 13-22% release within a day of incubation for NAC free acid vs NAC-Ca2+ and NAC-Mg2+salts, respectively) and slow and continuous complete release over 4 weeks without significant NAC-catalyzed degradation of PLGA. Release of NAC from NAC-Ca2+/PLGA implant was slower than that of NAC-Mg2+/PLGA consistent with the lower solubility of the former salt. NAC with its free thiol was rapidly converted to its cystine dimer in the presence of molecular oxygen. PLGA released samples in sealed and evacuated ampoules indicated>80% parent NAC remaining after the 1 month release analysis irrespective of initial NAC free acid and salt forms.
conclusionBy encapsulating the NAC-Mg2+ and NAC-Ca2+ salts in PLGA implants, the high initial burst, short release duration, and the general acid catalysis caused by the NAC free acid were each prevented and 1-month slow and continuous release was attained with minimal instability of the free thiol group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.